ArticleNeuropharmacology2008
Cannabidiol arrests onset of autoimmune diabetes in NOD mice.
Article in Neuropharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.
- The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review ofCannabis and cannabinoid research · 2021Pooled it
- Cannabinoids in immune system-related diseases: From bench to clinic.Chinese medical journal · 2026Review
- Cannabidiol exerts antiinflammatory effects but maintains T effector memory cell differentiation in humans.JCI insight · 2026Article
- Anti-inflammatory effects of cannabidiol in the treatment of type 1 diabetes: A mini review.World journal of diabetes · 2025Review
- Cardiovascular Effects of Cannabidiol: From Molecular Mechanisms to Clinical Implementation.International journal of molecular sciences · 2025Review
- Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans.Diabetologia · 2024Article
- Unraveling the Mechanisms of Cannabidiol's Pharmacological Actions: A Comprehensive Research Overview.Topics in current chemistry (Cham) · 2024Review
- Antibiofilm and Immune-Modulatory Activity of Cannabidiol and Cannabigerol in Oral Environments-In Vitro Study.Antibiotics (Basel, Switzerland) · 2024Article
- An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects.Molecules (Basel, Switzerland) · 2024Review
- The pharmacology and therapeutic role of cannabidiol in diabetes.Exploration (Beijing, China) · 2023Article
- Molecular and Cellular Mechanisms of Action of Cannabidiol.Molecules (Basel, Switzerland) · 2023Review
- The therapeutic potential of purified cannabidiol.Journal of cannabis research · 2023Review
- Cannabidiol for musculoskeletal regenerative medicine.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Modulation of pulmonary immune function by inhaled cannabis products and consequences for lung disease.Respiratory research · 2023Review
- Improved Anti-Biofilm Effect against the Oral CariogenicBiomedicines · 2023Article
- The Endocannabinoid System and Physical Exercise.International journal of molecular sciences · 2023Review
- Pharmacokinetics of cannabidiol-/cannabidiolic acid-rich hemp oil in juvenile cynomolgus macaques (Frontiers in veterinary science · 2023Article
- Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy.World journal of diabetes · 2022Review
- Review
- Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles.Biomedicines · 2022Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
We have previously reported that cannabidiol (CBD) lowers the incidence of diabetes in young non-obese diabetes-prone (NOD) female mice. In the present study we show that administration of CBD to 11-14 week old female NOD mice, which are either in a latent diabetes stage or with initial symptoms of diabetes, ameliorates the manifestations of the disease. Diabetes was diagnosed in only 32% of the mice in the CBD-treated group, compared to 86% and 100% in the emulsifier-treated and untreated groups, respectively. In addition, the level of the proinflammatory cytokine IL-12 produced by splenocytes was significantly reduced, whereas the level of the anti-inflammatory IL-10 was significantly elevated following CBD-treatment. Histological examination of the pancreata of CBD-treated mice revealed more intact islets than in the controls. Our data strengthen our previous assumption that CBD, known to be safe in man, can possibly be used as a therapeutic agent for treatment of type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.